IL-2R common γ-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 29, 2011, Pages 11977-11982

  Zhang, Qian ^a   Wang, Hong Yi ^a   Liu, Xiaobin ^a   Bhutani, Gauri ^a   Kantekure, Kanchan ^a   Wasik, Mariusz ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR GAMMA; MESSENGER RNA; NUCLEOPHOSPHIN ANAPLASTIC LYMPHOMA KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; LYMPHOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GENE SILENCING; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LUCIFERASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMIDS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 79961041326     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1100319108     Document Type: Article

References (38)

1. Li R, Morris SW (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28:372-412. (Pubitemid 351590540)
2. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23.
3. Wasik MA, et al. (2009) Anaplastic lymphoma kinase (ALK)-induced malignancies: Novel mechanisms of cell transformation and potential therapeutic approaches. Semin Oncol 36(2, Suppl 1):S27-S35.
4. Morris SW, et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284. (Pubitemid 24107549)
5. Shiota M, et al. (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567-1574. (Pubitemid 24163381)
6. Morris SW, et al. (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175-2188. (Pubitemid 27248229)
7. Fujimoto J, et al. (1996) Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93:4181-4186. (Pubitemid 26146730)
8. Bischof D, Pulford K, Mason DY, Morris SW (1997) Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17:2312-2325. (Pubitemid 27133318)
9. Kuefer MU, et al. (1997) Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90:2901-2910. (Pubitemid 27444183)
10. Zhang Q, et al. (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168:466-474. (Pubitemid 34014150)
11. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA (2006) Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 103:9964-9969. (Pubitemid 43993606)
12. Marzec M, et al. (2008) Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 105:20852-20857.
13. Zhang Q, Wang HY, Liu X, Wasik MA (2007) STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med 13:1341-1348. (Pubitemid 350073594)
14. Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480-490.
15. Overwijk WW, Schluns KS (2009) Functions of gammaC cytokines in immune homeostasis: Current and potential clinical applications. Clin Immunol 132:153-165.
16. Noguchi M, et al. (1993) Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73:147-157. (Pubitemid 23115456)
17. DiSanto JP, Müller W, Guy-Grand D, Fischer A, Rajewsky K (1995) Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci USA 92:377-381.
18. Cao X, et al. (1995) Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2:223-238.
19. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692. (Pubitemid 46273572)
20. Best JD, Carey N (2010) Epigenetic opportunities and challenges in cancer. Drug Discov Today 15:65-70.
21. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J (2006) SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 107:4130-4138. (Pubitemid 43726823)
22. Zhang Q, et al. (2009) Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis. Proc Natl Acad Sci USA 106:15843-15848.
23. Lu L, et al. (2009) ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry 48:3600-3609.
24. Zhang Q, et al. (2005) STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 102:6948-6953. (Pubitemid 40675422)
25. Zhang Q, et al. (2006) STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 108:1058-1064. (Pubitemid 44154645)
26. Qiu L, et al. (2006) Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108:2407-2415. (Pubitemid 44497526)
27. Ambrogio C, et al. (2009) NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 69:8611-8619.
28. Fabbri M, et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104:15805-15810. (Pubitemid 350035380)
29. Garzon R, et al. (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113:6411-6418.
30. Kishikawa S, Murata T, Kimura H, Shiota K, Yokoyama KK (2002) Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. Eur J Biochem 269:2961-2970. (Pubitemid 34754025)
31. Benetti R, et al. (2008) A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol 15:268-279. (Pubitemid 351654050)
32. Marzec M, et al. (2005) Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85:1544-1554. (Pubitemid 41662338)
33. Wan W, et al. (2006) Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107:1617-1623. (Pubitemid 43242400)
34. Galkin AV, et al. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 104:270-275. (Pubitemid 46068021)
35. Hehlmann R, Berger U, Hochhaus A (2005) Chronic myeloid leukemia: A model for oncology. Ann Hematol 84:487-497. (Pubitemid 41007019)
36. Garcia-Manero G (2008) Demethylating agents in myeloid malignancies. Curr Opin Oncol 20:705-710.
37. Wilson CB, Makar KW, Shnyreva M, Fitzpatrick DR (2005) DNA methylation and the expanding epigenetics of T cell lineage commitment. Semin Immunol 17:105-119. (Pubitemid 40289214)
38. Narasimhan S, Falkenberg VR, Khin MM, Rajeevan MS (2009) Determination of quantitative and site-specific DNA methylation of perforin by pyrosequencing. BMC Res Notes 2:104.